According to The Fly, Royal Bank of Canada analysts reduced Bausch Health Companies’ price objective from $17.00 to $12.00 in a report released on Tuesday. The price target set by the Royal Bank of Canada points to a potential increase from the stock’s current price of 35.75 percent.
Recently, comments on BHC were also made by a number of other equity research analysts. In a study released on May 11th, Bank of America reduced their target price for Bausch Health Companies from $25.00 to $12.00. On Monday, June 13th, JPMorgan Chase & Co. began covering Bausch Health Companies in a research note.
They assigned the business an “overweight” rating and a $12.00 price target. In a research report published on May 11th, BMO Capital Markets lowered its price objective on Bausch Health Companies from $26.00 to $15.00.
In a report published on May 11th, StockNews.com lowered Bausch Health Companies from a “buy” rating to a “hold” rating. Finally, on Monday, March 28th, TheStreet downgraded Bausch Health Companies from a “c-” rating to a “d+” rating in a research report.
Four research analysts have given the company’s shares a buy rating, while two have given the stock a hold rating. The stock currently has a “Moderate Buy” average rating and a $14.83 average price target, according to MarketBeat.
Pan Finance is a print journal and news website providing worldwide intelligence on finance, economics and global commerce. Known for our in-depth analysis and opinion pieces from esteemed academics and celebrated professionals; our readership consists of senior decision makers from across the globe.